Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?

被引:58
作者
Fischer, Barbara [1 ]
Marinov, Marin [1 ]
Arcaro, Alexandre [1 ]
机构
[1] Univ CHildrens Hosp, Div Clin Chem & Biochem, Zurich, Switzerland
关键词
small cett lung cancer; receptor tyrosine kinase; Gefitinib; Gleevec; c-Kit; Insulin-like growth factor; receptor; Epidermal growth factor; Phosph oi nosi tide 3-kinase; Mammalian target of; rapamycin; Ras;
D O I
10.1016/j.ctrv.2007.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small cell lung cancer (SCLC) is an aggressive form of lung cancer, which represents 13% of all. cases and is strongly associated with cigarette smoking. The survival of SCLC patients is dismal and has not greatly improved in the last 20 years, despite advances in chemotherapy regimens and a better understanding of SCLC biology. The development of resistance to chemotherapy and metastasis are commonly recognized as important causes of poor clinical. outcome in SCLC. Targeting receptor tyrosine kinase (RTK) signalling represents an attractive approach to develop new drugs for SCLC, in view of the accumulating data demonstrating that polypeptide growth factors play a key role in driving SCLC cell proliferation, chemoresistance and metastasis. The insulin-like growth factor-I receptor (IGF-IR), c-Kit, vascular endothelial. growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) have been identified as potential drug targets in SCLC. Moreover, downstream signalling mediators of RTKs, such as phosphoinositide 3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) may also represent attractive candidate motecules for anti-cancer therapies in SCLC. Here we witt review the available data concerning results with RTK inhibitors in SCLC and the clinical triais undertaken to investigate the potential of these compounds as anti-tumour agents in SCLC. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:391 / 406
页数:16
相关论文
共 216 条
  • [1] Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: A phase II clinical trial
    Altundag, O
    Altundag, K
    Boruban, C
    Silay, YS
    Turen, S
    [J]. CANCER, 2005, 104 (09) : 2033 - 2034
  • [2] Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer
    Araki, J
    Okamoto, I
    Suto, R
    Ichikawa, Y
    Sasaki, J
    [J]. LUNG CANCER, 2005, 48 (01) : 141 - 144
  • [3] Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation
    Arcaro, A
    Khanzada, UK
    Vanhaesebroeck, B
    Tetley, TD
    Waterfield, MD
    Seckl, MJ
    [J]. EMBO JOURNAL, 2002, 21 (19) : 5097 - 5108
  • [4] A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
    Asahina, H.
    Yamazaki, K.
    Kinoshita, I.
    Sukoh, N.
    Harada, M.
    Yokouchi, H.
    Ishida, T.
    Ogura, S.
    Kojima, T.
    Okamoto, Y.
    Fujita, Y.
    Dosaka-Akita, H.
    Isobe, H.
    Nishimura, M.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (08) : 998 - 1004
  • [5] Thalidomide and immunomodulatory drugs in the treatment of cancer
    Bamias, A
    Dimopoulos, MA
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2005, 14 (01) : 45 - 55
  • [6] RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide
    Bartling, B
    Yang, JY
    Michod, D
    Widmann, C
    Lewensohn, R
    Zhivotovsky, B
    [J]. CARCINOGENESIS, 2004, 25 (06) : 909 - 921
  • [7] HER-targeted tyrosine-kinase inhibitors
    Baselga, J
    Hammond, LA
    [J]. ONCOLOGY, 2002, 63 : 6 - 16
  • [8] The insulin-like growth factor-1 receptor as a target for cancer therapy
    Baserga, R
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) : 753 - 768
  • [9] Farnesyl transferase inhibitors
    Basso, AD
    Kirschmeier, P
    Bishop, WR
    [J]. JOURNAL OF LIPID RESEARCH, 2006, 47 (01) : 15 - 31
  • [10] Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation
    Belyanskaya, LL
    Hopkins-Donaldson, S
    Kurtz, S
    Simoes-Wüst, AP
    Yousefi, S
    Simon, HU
    Stahel, R
    Zangemeister-Wittke, U
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (05) : 755 - 763